Clinical trial · Interventional
Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients"
NCT05103644CI-TRIAL-00061901unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Statins, a major class of drugs for treatment of hypercholesterolemia, are widely used due to a notable prevention of cardiovascular disease, and accumulating evidence proposes a promising role of statins in breast cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atorvastatin 80mg | Drug | — | UNRESOLVED |
| placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- study
- description
- breast cancer patient received Atorvastatin 80 mg
- interventionNames
- Drug: Atorvastatin 80mg
- type
- PLACEBO_COMPARATOR
- label
- control group
- description
- breast cancer patient received placebo
- interventionNames
- Other: placebo
Primary outcomes (3)
- measure
- Ki-67 molecular
- timeFrame
- 3 month
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Confirmed breast cancer any stage confirmed by radiological and pathological or by clinical evaluation undergo surgery or receiving neo/adjuvant chemotherapy treatment 2. Age above 18 years 3. HER2 negative core biopsy 4. Adequate renal function: the calculated creatinine clearance should be ≥50 mL/min 5. Patients must be accessible for treatment and follow-up 6. Performance status of Eastern Cooperative Oncology Group (ECOG) ≤ 2 Exclusion Criteria: 1. Known hypersensitivity reaction to the investigational compounds or incorporated substances 2. patients who are unlikely to comply with trial requirements (eg, confusion, psychological or mood disturbances ,alcoholism, cardiac arrhythmia)
References
Publications (0)
Data not yet available
No reference posted for this study.